

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Dermatologic and Ophthalmologic Drugs Advisory Committee (DODAC) Meeting*  
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
October 13, 2017

**QUESTIONS**

---

1. **VOTE:** Do the clinical trials support the efficacy of netarsudil ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension?
  - a. If no, what additional trials would you recommend?
  
2. **VOTE:** Does the efficacy of netarsudil ophthalmic solution, demonstrated in the clinical trials, outweigh the safety risks identified for the drug product?
  - a. If no, what additional trials would you recommend?
  
3. **DISCUSSION:** Please discuss any suggestions you have concerning the proposed draft labeling of the product.